" class="no-js "lang="en-US"> Mike Rosenbluth - Medtech Alert
Wednesday, April 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mike Rosenbluth

Mike Rosenbluth

About Mike Rosenbluth

Founder and CEO of Swing Therapeutics. I am passionate about creating and delivering breakthrough innovation to fundamentally improve healthcare for us all. I am a scientist and engineer at heart with a PhD in biomedical engineering from UC Berkeley and UCSF.

Specialties: digital therapeutics, machine learning, genomics, life science venture capital, healthcare strategy, helping people live better lives

Related Story

Industry News

 Swing Therapeutics Selects Curavit to Provide Virtual Trial Site Services for Novel Digital Therapeutic Study for Fibromyalgia | Pharmtech Focus

Swing Therapeutics Selects Curavit to Provide Virtual Trial Site Services for Novel Digital Therapeutic Study for Fibromyalgia

June 29 2022

Curavit Clinical Research, a virtual contract research organization (VCRO), has been selected by digital therapeutics company, Swing […]